The packet lists no associated genes and no inheritance pattern for this condition, and it does not certify a specific underlying cause or mechanism. The definition describes the condition as a systemic vasculitis, meaning inflammation of blood vessels.

Diagnostic methods and classification criteria are not certified in this packet. The characteristic features named in the definition are asthma, transient pulmonary infiltrates, and hypereosinophilia.

FDA records in the packet list two products with active market status for this condition: mepolizumab (marketed as Nucala, a BLA approved on 2019-06-06) and benralizumab (marketed as Fasenra, a BLA approved on 2017-11-14). Orphan drug records in the packet also show an approved status for benralizumab and mepolizumab, and for avacopan (Tavneos) and rituximab (Rituxan), the latter two with indications described as ANCA-associated vasculitides that include Churg-Strauss syndrome. A selective Janus kinase 1 inhibitor from NS Pharma carries an orphan designation for this condition; a designation is not an approval. Other management approaches are not certified in this packet.

Prognosis, natural history, and long-term outcomes are not certified in this packet.

ClinicalTrials.gov records in the packet show numerous trials for this condition, with studies currently recruiting or active but not recruiting. Listed studies include phase 3 trials comparing benralizumab with mepolizumab (sponsored by AstraZeneca) and depemokimab with mepolizumab (sponsored by GlaxoSmithKline), phase 2 trials of NS-229, tezepelumab, and SHR-1703, and a recruiting study titled Benralizumab Effectiveness in EGPA from the European EGPA Study Group. Several recruiting records are registries or repositories for systemic vasculitis, including the Vasculitis Pregnancy Registry and the VCRC Tissue Repository. A trial title indicates the agent under study and does not establish an intervention's effect. ClinicalTrials.gov provides a searchable listing of studies for this condition.